Australian Telehealth Platform Eucalyptus Raises A $30 Million AUD Series B From Global Investors

The funding will go towards building out the behavioral health and chronic care modules of the platform to support brands in weight management, diabetes, and mental health

Australian telehealth platform Eucalyptus has raised a $30 million AUD Series B funding. The funding round was led by Silicon Valley-based NewView Capital, whose portfolio includes digital health companies 23andMe and Hims & Hers, with participation from existing investors Blackbird Ventures and W23, and new investor AirTree Ventures.

Recommended AI News: Voyager Digital to Lead Cryptocurrency Education for Pro Football Players

Eucalyptus is the largest vertically integrated telehealth platform in Australia, serving more than 200,000 patients. Since its founding in 2019, Eucalyptus has launched four demographic-focused brands that serve contraception and fertility, skincare, men’s health and sexual wellness. The company’s demographic and condition-specific digital health services provide patients with access to specialized healthcare providers that are well-versed in the issues and care that consumers demand. This new round of funding will allow the company to build out the behavioral health and chronic care modules of the platform to support brands in weight management, diabetes, and mental health.

To comprehensively address the future of behavioral health, Eucalyptus has built one core platform that underpins the operations behind all of their brands, providing a rapidly scalable infrastructure of high-quality healthcare providers, a repository of patient data, remote monitoring tools, and partnerships with pathology labs and pharmacies to drive holistic customer success. This results in a higher touch, higher quality relationship with patients, empowering them to make better health decisions and stay healthier longer.

Leveraging Australia’s strong reputation in health and wellness offerings, its growing tech ecosystem, and its similarities to other global healthcare models, Eucalyptus has a massive opportunity to build a comprehensive, demographic-focused digital health portfolio in primary care, in Australia and beyond.

Recommended AI News: Zeta Surgical Enters into Exclusive License Agreement with Leading Boston-based Hospital, Partners with Singapore’s National Neuroscience Institute

“As Australia’s tech ecosystem grows, it’s great to see more and more talent moving from professional services to building the next generation of fast-growing tech companies,” said Christina Fa of NewView Capital, “we were immediately impressed by the high-quality team Eucalyptus has built and believe the company is well positioned to become a global leader in digital care.”

“With Eucalyptus’ continued growth throughout Australia, we are thrilled with today’s announcement,” says founder Tim Doyle, “We’re excited to have NewView on board. We wanted a partner who believed a global healthcare company could originate from Australia, who had the experience to help us get there, and were willing to roll up their sleeves to help us advance the business. We believe we’ve got that with NewView.”

With the funding, Ravi Viswanathan, Founder and Managing Partner of NewView Capital, will be joining the Eucalyptus board.

Recommended AI News: Heifer International and IBM Work with Coffee and Cocoa Farmers in Honduras to Increase Access to Data and Global Markets